J Cancer 2018; 9(22):4255-4262. doi:10.7150/jca.26217

Research Paper

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line

Ondrej Fiala1,2✉, Petr Hosek2, Ondrej Sorejs1,2, Vaclav Liska2,3, Tomas Buchler4, Alexandr Poprach5, Radek Kucera6, Ondrej Topolcan6, Monika Sedivcova7, Jindrich Finek1

1. Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, Czech Republic
2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic
3. Department of Surgery, Medical School and University Hospital in Pilsen, Charles University, Czech Republic
4. Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Czech Republic
5. Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 543/7, 656 53 Brno, Czech Republic
6. Department of Immunochemistry, Medical School and University Hospital in Pilsen, Charles University, Czech Republic
7. Bioptic Laboratory, Ltd., Molecular Pathology Laboratory, Pilsen, Czech Republic

Abstract

The measurement of serum tumour markers is a simple and non-invasive method for assessing the response to systemic therapies in metastatic colorectal cancer (mCRC) and estimation of prognosis. The aim of our retrospective study was to evaluate the association of baseline serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) with outcome of patients with mCRC treated with combination of chemotherapy and monoclonal antibodies against epidermal growth factor receptor (anti-EGFR mAbs) in the first line. In our study, the cohort included 102 patients treated with therapy based on anti-EGFR mAbs between years 2011 and 2017 at Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Czech Republic. Serum samples were collected within one month before the initiation of treatment. In multivariate Cox analysis that included serum tumour markers and clinical baseline parameters show that high baseline serum CA 19-9 was significantly associated with worse progression-free survival (HR=1.871, p=0.0330) and also overall survival (HR=3.903, p=0.0006). We have not demonstrated association of baseline levels of CEA, TK and TPS with patients' outcome. CA 19-9 is commonly used serum tumour marker which is simple and readily available and its candidate prognostic importance in the setting of anti-EGFR therapy deserves to be studied in prospective trials.

Keywords: colorectal cancer, cetuximab, panitumumab, chemotherapy, tumor markers, serum carcinoembryonic antigen, carbohydrate antigen 19-9, thymidine kinase, tissue polypeptide specific antigen

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Fiala O, Hosek P, Sorejs O, Liska V, Buchler T, Poprach A, Kucera R, Topolcan O, Sedivcova M, Finek J. The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. J Cancer 2018; 9(22):4255-4262. doi:10.7150/jca.26217. Available from http://www.jcancer.org/v09p4255.htm